🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

T2 Biosystems regains Nasdaq compliance

EditorNatashya Angelica
Published 05/23/2024, 12:34 AM
TTOO
-

LEXINGTON, Mass. - T2 Biosystems, Inc. (NASDAQ:TTOO), a medical device company specializing in the rapid detection of sepsis-causing pathogens, announced on Monday that it has regained compliance with the Nasdaq's market value of listed securities requirement for continued listing on the Nasdaq Capital Market. This follows a period of non-compliance that began in late 2023.

Previously, on November 22, 2023, T2 Biosystems was notified of its non-compliance due to its failure to maintain a minimum market value of $35 million over 30 consecutive business days. In response, the company appealed for an exception, which was granted by the Nasdaq Hearings Panel on March 11, 2024, conditional upon demonstrating compliance by May 20, 2024.

To meet the Nasdaq's requirement, T2 Biosystems was required to maintain a market value of at least $35 million for a minimum of 10 consecutive trading days. The company successfully achieved this on May 16, 2024, and is now in full compliance with Nasdaq's listing requirements.

T2 Biosystems has developed a range of products for the rapid detection of infectious pathogens, including the T2Dx Instrument and various specialized panels for bacteria, candida, and antibiotic resistance genes. These products leverage the company's proprietary T2 Magnetic Resonance technology.

The press release also contained forward-looking statements regarding the company's future compliance with Nasdaq listing requirements and its strategic priorities. However, these statements are subject to various risks and uncertainties that could cause actual results to differ materially from the company's expectations.

The company's recent compliance achievement does not imply any endorsement of its future market performance or business outlook. This news is based on a press release statement from T2 Biosystems, Inc.

InvestingPro Insights

In light of T2 Biosystems' recent compliance with Nasdaq's market value requirements, a closer look at the company's financial health and stock performance through InvestingPro provides a nuanced perspective. As of the last twelve months leading up to Q1 2024, T2 Biosystems' market capitalization stands at $83.75 million USD, reflecting the company's efforts to stabilize its position in the market.

Yet, the financial metrics indicate a challenging landscape for the company. With a negative P/E ratio of -1.95, it is clear that T2 Biosystems has faced profitability issues, which is further supported by a significant gross profit margin decline to -314.2%. This suggests that the company's cost of goods sold far exceeds its revenue, a situation that can be unsustainable in the long term.

InvestingPro Tips also highlight several critical factors investors should consider. T2 Biosystems is quickly burning through cash and has a history of weak gross profit margins. Moreover, analysts do not expect the company to be profitable this year, and it has not been profitable over the last twelve months. These factors are essential to consider when assessing the company's future prospects.

On the performance front, the stock has experienced a large price uptick over the last six months, with a total return of 38.32%. Nevertheless, the one-year price total return reflects a steep decline of -80.73%, indicating significant volatility and uncertainty in the stock's performance. This volatility is something that potential investors should be wary of when considering T2 Biosystems as part of their portfolios.

For readers interested in a deeper analysis and more InvestingPro Tips for T2 Biosystems, there are additional insights available at https://www.investing.com/pro/TTOO. To enhance your investing strategy with these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With numerous additional tips listed in InvestingPro, investors can gain a comprehensive understanding of the company's financial health and stock performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.